Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $16.7 million.

  • Mimedx's Income from Continuing Operations rose 11259.2% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year decrease of 5244.27%. This contributed to the annual value of $42.0 million for FY2024, which is 3772.45% down from last year.
  • Mimedx's Income from Continuing Operations amounted to $16.7 million in Q3 2025, which was up 11259.2% from $9.6 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Income from Continuing Operations peaked at $51.3 million during Q4 2023, and registered a low of -$10.9 million during Q2 2022.
  • Its 5-year average for Income from Continuing Operations is $5.8 million, with a median of $7.4 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Mimedx's Income from Continuing Operations was 483969.85% (2022), while the steepest drop was 51090.5% (2022).
  • Mimedx's Income from Continuing Operations (Quarter) stood at $199000.0 in 2021, then surged by 4839.7% to $9.8 million in 2022, then skyrocketed by 421.75% to $51.3 million in 2023, then tumbled by 85.5% to $7.4 million in 2024, then skyrocketed by 125.17% to $16.7 million in 2025.
  • Its last three reported values are $16.7 million in Q3 2025, $9.6 million for Q2 2025, and $7.0 million during Q1 2025.